Equity
€231,376 from €1.7m in 2019
Equity fell by 87% in 7 years.
PARALLAXTER
Lifetime
11 annual accounts with figures on one time axispeak €2.3m (2019)
€519,928▲ 54.8%
lowest -€713,250 (2018)
-€59,595▲ €215,785
peak €1.7m (2019)
€231,376▼ 26.8%
€363,177▼ 33.2%
peak 9.4 FTE (2018)
4 FTEunchanged
Board13 names since 2018all names
4 directorsTristan SALOME and 3 others
Owners2 names in the annual accounts
100%V-NOVA
Documentsfilings and deeds
08-10-202623 days before the deadline
2026abbreviated format
Gross margin from €335,907 to €519,928Loss of €59,595Equity from €315,951 to €231,376Debts from €543,349 to €363,177Cash from €55,411 to €18,001
Key points
from the 2026 annual accountsLosses
-€2.3m in six years
Every financial year from 2020 to 2026 closed with a loss. 2024 was the heaviest.
Investments
€3,785 0.0 × depreciation
Green is investment, beige is depreciation.
Staff
4 FTE from 9.4 in 2018
Between 2018 and 2026, 57% of the full-time equivalents disappeared.
Filings
11 annual accounts since 2015
Five of the last ten came late. The 2018 accounts came latest: 54 days after the end of the period.
At the same address
21 companies
Net result +78%: other schema
Checked score
67
Healthy
Financially stronger than 34% of micro companies in research and development (NACE 72)
Probability in this band: 0.55% to 1.5%
Bankruptcy probability within 12 months
0.9% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.1% across 932 companies (NACE 72, micro).
About 9 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.4%lowest value
01-2025: 0.4%● unchanged vs 12-2024lowest value
02-2025: 0.4%● unchanged vs 01-2025lowest value
03-2025: 0.4%● unchanged vs 02-2025lowest value
04-2025: 0.4%● unchanged vs 03-2025
05-2025: 0.4%● unchanged vs 04-2025
06-2025: 0.4%● unchanged vs 05-2025
07-2025: 0.4%● unchanged vs 06-2025
08-2025: 0.4%● unchanged vs 07-2025
09-2025: 0.5%▲ +0.1 percentage points vs 08-2025
10-2025: 0.6%▲ +0.1 percentage points vs 09-2025
11-2025: 0.8%▲ +0.2 percentage points vs 10-2025
12-2025: 0.9%▲ +0.1 percentage points vs 11-2025
01-2026: 0.9%● unchanged vs 12-2025
02-2026: 0.9%● unchanged vs 01-2026
03-2026: 0.9%● unchanged vs 02-2026
04-2026: 0.9%● unchanged vs 03-2026
05-2026: 0.9%● unchanged vs 04-2026
06-2026: 0.9%● unchanged vs 05-2026
07-2026: 0.9%● unchanged vs 06-2026
08-2026: 1.0%▲ +0.1 percentage points vs 07-2026
09-2026: 1.1%▲ +0.1 percentage points vs 08-2026highest value
10-2026: 0.9%▼ -0.2 percentage points vs 09-2026
11-2026: 0.9%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
Loss of €59,595, the second in a row (financial year 2026)
Liquidity: current ratio 0.36, cash €18,001, halved
lowers risk
Figures for financial year 2026 (filed on 08-10-2026)
Equity €231,376 (38.9% of total assets)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro). It does better than 38% of them on solvency, 34% on liquidity, 39% on profitability and 24% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-03-2026.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 4,805 companies had the same profile as PARALLAXTER has now. Each dot stands for 13 companies, two years later.
88.1%
were still trading
9.8%
stopped another way
2.0%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of PARALLAXTER itself: 0.9% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 4,805 companies, not a prediction for PARALLAXTER. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €15,000 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.36 (0.43 in 2025), below 1. Short-term debt is 15% and cash 3% of total assets. 61.1% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Persistent losses
Two consecutive loss-making years (2025 and 2026); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2026Net result per financial year
1819202122242526
2018 to 2026 · latest year -€59,595
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2026 was due by 31-10-2026 and was filed on 08-10-2026, 23 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2026
23 days early
2025
4 days late
2024
24 days early
2022
31 days early
2021
24 days late
2020
23 days early
2019
23 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 14 days before the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-03-2027 and is due by 31-10-2027. Nothing is late today. The company usually files around 8 October (3 of the last 3 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-03-2027 year end31-10-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0564848024
3 directors appointed, 1 resignation
Resignation: Gaël Honorez · Appointments: Antonio Filippi, Pierdavide Marcolongo (chair of the board) and Gianluca Meardi · actionnaire unique holds all the shares · General meeting of 24-11-2023 · Gazette deed
Capital contribution of €1,045,456.37
Contributions: Tristan SALOME (€75,000); V-NOVA INTERNATIONAL LTD (€640,052.71) · Issue of 189,744 shares · Issue of 21,446 shares · General meeting of 24-11-2023 · Gazette deed
Resignation: Matthieu LABEAU (director)
Director discharge: Matthieu LABEAU · General meeting of 16-11-2021 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PARALLAXTER Koekelberg | €0.6m | €0.5m | 38.9% | 4 |
| RAYFERENCE Brussels | €0.5m | €0.5m | 27.6% | 4.1 |
| CTI Clinical Trial and Consulting Services Belgium Woluwe-Saint-Pierre | €0.7m | €1.3m | 55.8% | 8.7 |
| CABINET MEDICAL CHAPMAN Spa | €0.5m | €0.5m | 17.0% | 2.9 |
| SILLAR CLINICAL Sint-Martens-Latem | €0.8m | €0.6m | 10.5% | 5.9 |
| STAPHYT BELGIQUE Perwez | €1.3m | €0.6m | 4.0% | 5 |
| TRACE Leuven | €0.5m | €0.9m | 7.6% | 7.8 |
These companies have the same main activity as PARALLAXTER: other research and development on natural sciences (NACE 72109). They are comparable in size and age: total assets between €497,000 and €1.3m, founded between 2009 and 2018.
Official details
Source: KBO- Status
- Active since 20-10-2014Normal situation
- Registered office
- 22 active companies are registered at this addressSource: KBO register, as of 9 November 2026.
- Activity
- Other research and development on natural sciencesNACE 72109and 2 others
- Joint committee
- 200Auxiliary committee for white-collar workers · annual accounts 31-03-2026
- Establishment unit
- 2.237.383.9841081 Koekelberg, since 20-10-2014
- Financial year end
- 31 March
- Peppol
- Reachable since 08-12-2025
Annual accounts to 31-03-2026
- ≈ €1.2mestimated
- €594,553▼ 30.8%
- Employeeson 31-03-2026
- 4=
- Filing
- Filed on 08-10-2026, 23 days before the end of the filing period
Insights on PARALLAXTER
PARALLAXTER files the abbreviated format. That format states no turnover. The gross margin rose from €26,827 in 2015 to €519,928 in 2026.
V-NOVA holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PARALLAXTER
- What is the company number of PARALLAXTER?
- The company number of PARALLAXTER is 0564.848.024. The VAT number is the same number with BE in front: BE 0564.848.024.
- Where is PARALLAXTER based?
- The registered office is at Deschampheleerstraat 26, 1081 Koekelberg.Company details
- What does PARALLAXTER do?
- According to the KBO register, the main activity is other research and development on natural sciences (NACE 72109).
- What is the legal form of PARALLAXTER?
- PARALLAXTER is a private limited company (BV).
- When was PARALLAXTER founded?
- PARALLAXTER was founded on 20-10-2014.
- Is PARALLAXTER still active?
- Yes, PARALLAXTER is an active enterprise in the KBO register.
- How many employees does PARALLAXTER have?
- PARALLAXTER had an average of 4 full-time equivalents in financial year 2026, according to the filed annual accounts.Financials
- Which joint committee does PARALLAXTER fall under?
- In its 31-03-2026 annual accounts, PARALLAXTER states joint committee 200 (Auxiliary committee for white-collar workers).
- What is the turnover of PARALLAXTER?
- The turnover in financial year 2026 is ≈ €1.2m. This figure is estimated from the gross margin of €519,928 and 2,275 comparable companies of the same size. It probably lies between €740,000 and €2.1m. It is a rough estimate.
- Is PARALLAXTER profitable?
- In financial year 2026, PARALLAXTER made a loss of €59,595.
- Where can I find the annual accounts of PARALLAXTER?
- PARALLAXTER filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
- When are the next annual accounts of PARALLAXTER due?
- PARALLAXTER must file the annual accounts for financial year 2027 by 31-10-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.